Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ribosome Profiling02:24

Ribosome Profiling

3.4K
Ribosome profiling or ribo-sequencing is a deep sequencing technique that produces a snapshot of active translation in a cell. It selectively sequences the mRNAs protected by ribosomes to get an insight into a cell’s translation landscape at any given point in time.
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
3.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Triphase Interfacial Nucleation Enables Microneedle-Templated Metal-Organic Framework Coating for <i>In Situ</i> DNA Capture and Release.

Analytical chemistry·2026
Same author

Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.

Translational cancer research·2026
Same author

Letter to the Editor: "What every intensivist should know about extracorporeal CO₂ removal in ARDS".

Journal of critical care·2026
Same author

Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.

Blood advances·2026
Same author

DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

[<i>Yiqi Jiedu</i> Formula inhibits proliferation, invasion and migration of nasopharyngeal carcinoma cells by inhibiting the AKT1/GLUT1 signaling pathway].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2026

Related Experiment Video

Updated: May 26, 2025

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection
09:19

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Published on: July 6, 2022

4.8K

Spatial transcriptomics reveals prognostically LYZ+ fibroblasts and colocalization with FN1+ macrophages in diffuse

Liyuan Dai1, Ning Lou1,2, Liling Huang1

  • 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Cancer Immunology, Immunotherapy : CII
|February 25, 2025
PubMed
Summary
This summary is machine-generated.

This study identified specific fibroblast and macrophage subtypes in diffuse large B-cell lymphoma (DLBCL) that predict patient outcomes. These subtypes and their associated genes may serve as biomarkers for improved DLBCL treatment strategies.

Keywords:
Cancer-associated fibroblastsDiffuse large B cell lymphomaPrognostic markerSpatial transcriptomicsTumor-associated macrophages

More Related Videos

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

2.5K
Spatially Compact Arrangement of Larval Zebrafish Sections for Spatial Transcriptomic Analysis
07:40

Spatially Compact Arrangement of Larval Zebrafish Sections for Spatial Transcriptomic Analysis

Published on: May 16, 2025

57

Related Experiment Videos

Last Updated: May 26, 2025

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection
09:19

Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection

Published on: July 6, 2022

4.8K
Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
07:43

Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics

Published on: May 3, 2024

2.5K
Spatially Compact Arrangement of Larval Zebrafish Sections for Spatial Transcriptomic Analysis
07:40

Spatially Compact Arrangement of Larval Zebrafish Sections for Spatial Transcriptomic Analysis

Published on: May 16, 2025

57

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with variable patient outcomes.
  • The tumor microenvironment (TME), including fibroblasts and macrophages, significantly influences DLBCL progression.
  • Understanding these cellular components is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify and characterize distinct fibroblast and macrophage subtypes within the DLBCL TME.
  • To determine the prognostic significance of these subtypes and their associated genes.
  • To explore their potential as biomarkers for patient stratification and therapeutic development.

Main Methods:

  • A multi-omics approach integrating spatial and bulk transcriptomics, IHC, mIF, and plasma samples.
  • Identification of hub genes for LYZ+ fibroblasts and FN1+ macrophages using Cox regression and random forest analyses.
  • Validation of prognostic markers in DLBCL and non-small cell lung cancer (NSCLC) cohorts.

Main Results:

  • Two distinct fibroblast and macrophage subtypes were identified: LYZ+ fibroblasts and FN1+ macrophages.
  • Higher infiltration of LYZ+ fibroblasts correlated with better prognosis and increased FN1+ macrophage infiltration.
  • Specific hub genes (e.g., LYZ, LILRB4, FN1, COL1A2, COL3A1) were validated as independent prognostic markers in DLBCL and NSCLC.

Conclusions:

  • LYZ+ fibroblasts and FN1+ macrophages are prognostically relevant in DLBCL.
  • The identified hub genes represent potential biomarkers for predicting patient outcomes.
  • These findings offer insights for improving therapeutic strategies and patient management in DLBCL.